Quantum Biopharma (NASDAQ:QNTM) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Quantum Biopharma (NASDAQ:QNTM) in a report published on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $8.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Weiss Ratings raised shares of Quantum Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. Wall Street Zen raised Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Quantum Biopharma presently has an average rating of “Hold” and a consensus price target of $8.00.

Quantum Biopharma Stock Up 1.3%

NASDAQ:QNTM opened at $3.08 on Monday. The company’s 50 day moving average is $3.28 and its 200-day moving average is $3.95. Quantum Biopharma has a 12 month low of $2.07 and a 12 month high of $21.00. The firm has a market cap of $19.71 million, a price-to-earnings ratio of -0.56 and a beta of 0.45.

Quantum Biopharma (NASDAQ:QNTM) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06).

Institutional Investors Weigh In On Quantum Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of QNTM. Platform Technology Partners bought a new position in Quantum Biopharma during the first quarter worth $199,000. Jane Street Group LLC bought a new stake in Quantum Biopharma in the 4th quarter valued at $80,000. Finally, Virtu Financial LLC bought a new stake in Quantum Biopharma in the 4th quarter valued at $76,000. Institutional investors and hedge funds own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.